| 05/08 | Eisai - baseball legend bernie williams teams up with eisai and advocacy partners to la.. | AQ |
| 05/08 | EISAI : CONSOLIDATED FINANCIAL REPORT for the Three-Month Period Ended June 30,2022 | PU |
| 05/08 | EISAI : FY 2022 (Ending March 31, 2023) First Quarter Financial Results Reference Data | PU |
| 04/08 | Merck and eisai provide update on phase 3 leap-002 trial evaluating keytruda (pembroliz.. | AQ |
| 04/08 | Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and.. | AQ |
| 04/08 | Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial | AQ |
| 03/08 | EISAI : and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial Ev.. | PU |
| 26/07 | Latest data on lecanemab to be presented at Alzheimer's Association International Confe.. | AQ |
| 26/07 | Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series | AQ |
| 26/07 | Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022 | AQ |
| 26/07 | EISAI : To present the latest lecanemab data, including aria-e and subcutaneous formulatio.. | PU |
| 12/07 | Interim Report for the period April - June 2022 | AQ |
| 06/07 | Eisai Co., Ltd. - THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS.. | AQ |
| 06/07 | U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application o.. | AQ |
| 06/07 | The FDA accepts BLA and grants priority review for lecanemab for treatment of early Alz.. | AQ |
| 24/06 | Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglect.. | AQ |
| 22/06 | PRESSWIRE GLOBAL NEWS DISTRIBUTION : ProMIS Neurosciences Announces Filing of Form 10 Regi.. | AQ |
| 22/06 | Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed .. | AQ |
| 08/06 | EISAI : Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the.. | PU |
| 06/06 | Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 202.. | AQ |
| 06/06 | EISAI PRESENTS NEW FINDINGS FOR ANTI : #5513)Poster Presentation Features Analyses Based o.. | PU |
| 03/06 | Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting | AQ |
| 30/05 | EISAI : Announcement of a Summary Share Exchange (kan'i kabushiki kokan) to Make Sunplanet.. | PU |
| 27/05 | Eisai Contributes to the Science of Cancer Medicine at ASCO 2022 | AQ |
| 27/05 | EISAI : MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formula.. | AQ |
| 20/05 | EISAI : “MOVICOL® HD” LaunchedA New Dosage Form Added to Polyethylene Glycol C.. | PU |
| 10/05 | Eisai Initiates Preparation for New Drug Application, Based on the Results of an Invest.. | AQ |
| 10/05 | Eisai completes rolling submission to the FDA of lecanemab for early Alzheimer's diseas.. | AQ |
| 03/05 | EISAI : Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the.. | PU |
| 28/04 | Interim Report for the period January - March 2022 | AQ |
| 27/04 | Modeling published in Neurology and Therapy suggests that lecanemab could delay progres.. | AQ |
| 08/04 | Biogen's Statement on the Final National Coverage Determination for Amyloid-Beta Target.. | AQ |
| 08/04 | Eisai statement on the centers for medicare and medicaid services | AQ |
| 08/04 | EISAI : Statement on the centers for medicare and medicaid services' national coverage det.. | PU |
| 01/04 | EISAI : Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengt.. | PU |
| 31/03 | Meagan good shares her scare with uterine cancer to encourage people to spot the early .. | AQ |
| 28/03 | EISAI : Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibito.. | AQ |
| 28/03 | EISAI : Announcement about an approval for additional indication of Jyseleca®, JAK inhibit.. | PU |
| 23/03 | Eisai Co., Ltd - LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKE.. | AQ |
| 22/03 | Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship t.. | AQ |
| 22/03 | SYSMEX PRESENTS ACADEMIC REPORT IN E : (ad/pdtm 2022) | PU |
| 22/03 | EISAI : Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting | AQ |
| 17/03 | Biogen Announces Peer-Reviewed Publication of ADUHELM Phase 3 EMERGE and ENGAGE Data in.. | AQ |
| 15/03 | Eisai - ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMER'S DISEASE TREATMENT COLLABORATI.. | AQ |
| 15/03 | EISAI : Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration .. | AQ |
| 15/03 | Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments | AQ |
| 15/03 | EISAI : ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMER‘S DISEASE TREATMENT COLLABOR.. | PU |
| 11/03 | Latest lecanemab data to be presented at the AD/PD™ congress | AQ |
| 11/03 | Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical.. | AQ |
| 11/03 | EISAI : TO PRESENT NEW LECANEMAB DATA EXPLORING DISTINCT MECHANISM OF ACTION AND CLINICAL .. | PU |
| 09/03 | EISAI : Certified as the 2022 health and productivity management outstanding organization .. | PU |
| 07/03 | Eisai initiates submission of application data under the prior assessment consultation .. | AQ |
| 07/03 | LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients w.. | AQ |
| 07/03 | EISAI : Lenvima®（lenvatinib）in combination with keytruda®（pembrolizum.. | PU |
| 04/03 | Eisai initiates submission of application data of lecanemab under the prior assessment .. | AQ |
| 28/02 | Eisai and Merck & Co., Inc. - LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approv.. | AQ |
| 25/02 | EISAI : LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically.. | AQ |
| 25/02 | EISAI : LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Approved in Japan for Radical.. | PU |
| 10/02 | Eisai submits formal comments to the centers for medicare and medicaid services' propos.. | AQ |
| 10/02 | EISAI : Submits formal comments to the centers for medicare and medicaid services' propose.. | PU |
| 03/02 | EISAI : Reference Data | PU |
| 03/02 | Interim Report for the period October - December 2021 | AQ |
| 03/02 | EISAI : CONSOLIDATED FINANCIAL REPORT for the Nine-Month Period Ended December 31, 2021 | PU |
| 03/02 | EISAI : FY 2021 (Ended March 31, 2022) Third Quarter Financial Results Reference Data | PU |
| 01/02 | Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021 | AQ |
| 01/02 | EISAI : Receives the tokyo governor prize for corporate governance of the year® 2021 | PU |
| 31/01 | EISAI : Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiw.. | AQ |
| 31/01 | EISAI : Lenvima®（lenvatinib）in combination with keytruda®（pembrolizum.. | PU |
| 28/01 | Eisai announces results and continued support of initiatives for elimination of neglect.. | AQ |
| 28/01 | Biogen Inc. - Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM | AQ |
| 28/01 | Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglect.. | AQ |
| 28/01 | EISAI : Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM | AQ |
| 28/01 | EISAI : ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTE.. | PU |
| 21/01 | Eisai - Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib.. | AQ |
| 20/01 | EISAI : Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) P.. | AQ |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (België)
Rapport
